04:09 PM EDT, 08/14/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) reported a Q2 loss late Wednesday of $0.42 per diluted share, narrowing from the loss of $1.16 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.51.

Revenue in the quarter ended June 30 rose to $30.9 million from $5.19 million a year earlier.

Analysts surveyed by Capital IQ expected $29.1 million.

Price: 9.73, Change: +0.15, Percent Change: +1.57